İsmail Bayrakçı

Dr. İsmail Bayrakçı


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BKBaris Koksal
Baris Koksal
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
DGDeniz Can Guven
Deniz Can Guven
FKFatih Köse
Fatih Köse
GKGörkem Köymen
Görkem Köymen
ZAZafer ARIK
Zafer ARIK
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in Türkiye between January 2014 and March 2025. Clinical, pathological, and molecular data—including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification—was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan–Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3–4 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.

21 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FAFahri Akgül
Fahri Akgül
IGivo gokmen
ivo gokmen
İBİsmail Bayrakçı
İsmail Bayrakçı
DDDidem Divriklioglu
Didem Divriklioglu
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
BEBülent Erdoğan
Bülent Erdoğan
Background: The Naples Prognostic Score (NPS) is a composite inflammation–nutrition index whose prognostic value has been scarcely examined in extensive-stage small cell lung cancer (ES-SCLC). This study aimed to evaluate the prognostic significance of the NPS in this setting. Methods: A retrospective analysis was performed on 142 patients diagnosed with ES-SCLC between March 2014 and June 2024. The NPS was calculated using the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), serum albumin, and total cholesterol levels. Patients were classified into three NPS categories (0, 1–2, and 3–4), and subsequently dichotomized into low-risk (0–2) and high-risk (3–4) groups. Survival outcomes were assessed using Kaplan–Meier estimates and multivariate Cox regression models. Results: Median overall survival (OS) was significantly longer in the low-risk group compared to the high-risk group (10.3 vs. 6.3 months; p = 0.012). High NPS remained an independent predictor of reduced OS (HR: 1.45; 95% CI: 1.02–2.06; p = 0.041). The prognostic strength of the NPS was primarily driven by low LMR and hypoalbuminemia, which were individually associated with worse outcomes. Conclusions: The NPS may serve as a simple, accessible, and independent prognostic tool in ES-SCLC, potentially aiding in clinical risk stratification and treatment planning.

7 April 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
SYSendag Yaslikaya
Sendag Yaslikaya
MMMartin Mildanoğlu
Martin Mildanoğlu
ACAlper Coskun
Alper Coskun
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal
OKOsman Köstek
Osman Köstek
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was to analyze the real-world clinical results of second-line treatments in progression after Atez/Bev and to determine the factors affecting prognosis. Materials and Methods: Fifty-eight patients treated with second-line sorafenib, regorafenib, and cabozantinib for progression after first-line Atez/Bev for advanced/metastatic HCC from 20 centers in Türkiye between October 2020 and June 2024 were retrospectively analyzed. Responses were evaluated by Response criteria, specifically Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Median overall survival (OS) and progression-free survival (PFS) were computed with the Kaplan–Meier method. The Cox regression model was utilized to analyze multivariate analyses. Results: About 82.8% of the patients were male and the median age of the whole group was 62 (range, 18-78) years. All patients progressed after first-line Atez/Bev and were given second-line treatment. The most commonly used second-line treatment option was sorafenib (70.7%), followed by regorafenib (12.1%) and cabozantinib (10.3%). Both median PFS (4.1 months) and median OS (7.8 months) were longer in patients treated with sorafenib compared to other treatments. In univariate analyses, Child–Pugh score B, alpha-fetoprotein (AFP) levels (>200 ng/mL), extrahepatic spread, and Prognostic Nutritional Index (PNI) < 47.6 substantially raised the risk of overall mortality. Multivariate analysis showed that extrahepatic spread (HR (Hazard ratio): 0.41, P = .012), PNI level (HR: 0.24, P =.005), and AFP level (HR:1.97, P = .049) were independent predictors of OS. Conclusion: Although second-line therapies after Atez/Bev show different degrees of efficacy, survival rates are consistent with the literature. Extrahepatic spread, AFP level, and PNI level are the main prognostic factors. In light of this information, personalized treatment strategies may improve outcomes for this challenging patient group. Cite this article as: Majidova N, Yaslıkaya S, Mıldanoglu MM, et al. Efficacy of second-line treatments after atezolizumab and bevacizumab in advanced hepatocellular carcinoma and related prognostic factors: A multicenter study by the turkish oncology group (TOG). Turk J Gastroenterol. 2025;36(5):293-301.

18 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FAFahri Akgül
Fahri Akgül
IGivo gokmen
ivo gokmen
İBİsmail Bayrakçı
İsmail Bayrakçı
DDDidem Divriklioglu
Didem Divriklioglu
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
BEBülent Erdoğan
Bülent Erdoğan
To evaluate the prognostic value of the Naples Prognostic Score (NPS)—a composite inflammation–nutrition index—in extensive-stage small cell lung cancer (ES-SCLC), a disease setting in which its application has been scarcely examined to date. A retrospective analysis was performed on 142 patients diagnosed with ES-SCLC between March 2014 and June 2024. The NPS was calculated using neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), serum albumin, and total cholesterol levels. Patients were classified into three NPS categories (0, 1–2, and 3–4), then dichotomized into low-risk (0–2) and high-risk (3–4) groups. Survival outcomes were assessed using Kaplan–Meier estimates and multivariate Cox regression models. Median overall survival (OS) was significantly longer in the low-risk group compared to the high-risk group (10.3 vs. 6.3 months; p = 0.012). High NPS remained an independent predictor of reduced OS (HR: 1.45; 95% Cl: 1.02–2.06; p = 0.041). The prognostic strength of the NPS appeared to be primarily driven by two of its components—low LMR and hypoalbuminemia—which were individually associated with worse outcomes. These findings suggest that the NPS may serve as a simple, accessible, and independent prognostic tool in ES-SCLC, potentially aiding in clinical risk stratification and treatment planning.

4 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDidem Divriklioglu
Didem Divriklioglu
İBİsmail Bayrakçı
İsmail Bayrakçı
GKGizem bakır kahveci
Gizem bakır kahveci
IGivo gokmen
ivo gokmen
DKDicle yurdatap koç
Dicle yurdatap koç
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
Background/Objectives: Clinical outcomes with immune checkpoint inhibitors (ICIs), such as nivolumab, vary among patients with metastatic non-small cell lung cancer (NSCLC). The Lung Immune Prognostic Index (LIPI) may help stratify prognosis. This study evaluated the prognostic significance of LIPI in patients receiving second- or third-line nivolumab and developed a nomogram for individualized survival estimation. Methods: This single-center retrospective study included 142 patients with metastatic NSCLC who received second- or third-line nivolumab between February 2022 and December 2024, after progression on platinum-based chemotherapy. LIPI was calculated from baseline values obtained within 14 days before nivolumab initiation, based on a derived neutrophil-to-lymphocyte ratio (dNLR) > 3 and lactate dehydrogenase (LDH) > 225 U/L (institutional upper limit of normal), classifying patients as good-, intermediate-, or poor-risk (0, 1, or 2 factors, respectively). Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan–Meier method; independent prognostic factors were assessed by multivariable Cox regression, and a prognostic nomogram combining ECOG performance status, serum albumin, and LIPI was developed and internally validated. Results: By LIPI, 34.5%, 45.1%, and 20.4% of patients were at good, intermediate, and poor risk, respectively. Objective response and disease control rates were 29.6% and 55.6%. Median OS and PFS were 19.3/8.0/3.1 and 8.6/3.1/2.5 months across good, intermediate, and poor LIPI groups (log-rank p < 0.001). In multivariable analysis, ECOG 2 (hazard ratio [HR], 4.94), albumin per 1 g/dL (HR 0.27), and poor versus good LIPI (HR 3.74) were independently associated with OS. A nomogram combining these three factors showed acceptable discrimination (optimism-corrected Harrell C-statistic 0.742). Conclusions: LIPI was independently associated with prognosis in this cohort. Combining LIPI with ECOG and albumin may aid individualized risk assessment, pending external validation.

Verified
Journal Article
Open access
PDF file
İBİsmail Bayrakçı
İsmail Bayrakçı
DDDidem Divriklioglu
Didem Divriklioglu
GKGizem bakır kahveci
Gizem bakır kahveci
TATayyip İlker Aydın
Tayyip İlker Aydın
DKDicle yurdatap koç
Dicle yurdatap koç
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
Background/Objectives: Kaposi sarcoma (KS) is an HHV-8-associated angioproliferative malignancy with heterogeneous clinical presentation. Early lesions may be overlooked or misattributed to benign conditions, potentially causing diagnostic delay. We evaluated whether diagnostic delay was associated with survival outcomes in a real-world KS cohort. Methods: We retrospectively analyzed 87 consecutive patients with histologically confirmed KS diagnosed between 2007 and 2025. Diagnostic delay was defined as the interval between first patient-reported lesion/symptom recognition documented in medical records and histological diagnosis. An exploratory, maximally selected log-rank method was used to identify the delay cut-off that best separated overall survival (OS). OS and progression-free survival (PFS) were analyzed using Kaplan–Meier estimates, log-rank tests, and Cox regression models. Results: The exploratory optimal cut-off for diagnostic delay was 6.5 months, defining early (≤6.5 months; n = 46) and late (>6.5 months; n = 41) diagnosis groups. Median OS was 202.2 months (95% CI 62.3–342.1) in the early group and 92.9 months (95% CI 61.8–124.0) in the late group (log-rank p < 0.001). Late diagnosis was associated with a higher risk of death (HR 3.6, 95% CI 1.6–8.1; p = 0.001). This association was attenuated after multivariable adjustment and was no longer statistically significant (adjusted HR, 1.711, 95% CI 0.696–4.207; p = 0.242). Patients with late diagnosis were older (median 74 vs. 67 years, p = 0.004), had greater comorbidity burden (39.0% vs. 13.0%; p = 0.005), and more frequently had lymphedema (19.5% vs. 4.3%; p = 0.041). Conclusions: In this single-center KS cohort, longer diagnostic delay was associated with poorer post-diagnosis overall survival in unadjusted analyses, while this association was attenuated after multivariable adjustment. The exploratory 6.5-month threshold identified a subgroup with less favorable survival; however, this data-driven cut-off should be considered hypothesis-generating. These findings support efforts to improve early recognition, biopsy, and referral in KS, particularly in older and more comorbid patients.